Syncona Creates Second Gene Therapy Company With £25m Financing
This article was originally published in Scrip
Executive Summary
The Wellcome Trust's investment subsidiary Syncona LLP has put £25m of series A financing into a new gene therapy company, Freeline Therapeutics, spun off from University College London (UCL) via its technology transfer arm UCL Business PLC. Freeline's initial focus will be on bleeding disorders.